Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia 1

Interventions

Imatinib Mesylate 12nilotinib 3bosutinib 3peginterferon alfa-2a 2asciminib 2Dasatinib 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1flumatinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Interferons 1Dexamethasone 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Antilymphocyte Serum 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Tyrosine Kinase Inhibitors × Myeloid × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡